Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS)
CNY 62.27
(-1.16%)
CNY 62.27
(-1.16%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.22 Billion CNY | -390.76% |
| 2022 | -249.24 Million CNY | 72.7% |
| 2021 | -913.06 Million CNY | 17.15% |
| 2020 | -1.1 Billion CNY | -15824.79% |
| 2019 | -6.92 Million CNY | 94.44% |
| 2018 | -124.4 Million CNY | -1158.61% |
| 2017 | -9.88 Million CNY | 41.94% |
| 2016 | -17.02 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -990.29 Million CNY | 19.04% |
| 2024 Q2 | -1.35 Billion CNY | -37.25% |
| 2024 Q3 | -1.25 Billion CNY | 10.04% |
| 2023 Q4 | -1.22 Billion CNY | -13.92% |
| 2023 Q2 | -822.94 Million CNY | -891.61% |
| 2023 FY | -1.22 Billion CNY | -390.76% |
| 2023 Q1 | -82.99 Million CNY | 66.7% |
| 2023 Q3 | -1.07 Billion CNY | -30.48% |
| 2022 Q3 | -329.49 Million CNY | 57.01% |
| 2022 Q4 | -249.24 Million CNY | 24.35% |
| 2022 Q2 | -766.4 Million CNY | 11.41% |
| 2022 Q1 | -865.14 Million CNY | 5.25% |
| 2022 FY | -249.24 Million CNY | 72.7% |
| 2021 FY | -913.06 Million CNY | 17.15% |
| 2021 Q1 | -1.3 Billion CNY | -18.5% |
| 2021 Q4 | -913.06 Million CNY | 6.49% |
| 2021 Q3 | -976.4 Million CNY | 19.83% |
| 2021 Q2 | -1.21 Billion CNY | 6.73% |
| 2020 Q1 | -1.09 Billion CNY | -15718.37% |
| 2020 FY | -1.1 Billion CNY | -15824.79% |
| 2020 Q3 | -1.14 Billion CNY | -1.37% |
| 2020 Q2 | -1.13 Billion CNY | -3.23% |
| 2020 Q4 | -1.1 Billion CNY | 3.8% |
| 2019 Q1 | -102.57 Million CNY | 17.55% |
| 2019 Q2 | -68.89 Million CNY | 32.84% |
| 2019 Q3 | -40.79 Million CNY | 40.78% |
| 2019 Q4 | -6.92 Million CNY | 83.04% |
| 2019 FY | -6.92 Million CNY | 94.44% |
| 2018 FY | -124.4 Million CNY | -1158.61% |
| 2018 Q4 | -124.4 Million CNY | 0.0% |
| 2017 FY | -9.88 Million CNY | 41.94% |
| 2016 FY | -17.02 Million CNY | 0.0% |